J Korean Med Assoc.  2014 Apr;57(4):343-347. 10.5124/jkma.2014.57.4.343.

Sclerotherapy of cystic lymphangioma

• Won JH

• KMID: 2064892
• DOI: http://doi.org/10.5124/jkma.2014.57.4.343

Abstract

Cystic lymphangioma is a congenital lymphatic malformation that occurs most commonly in the head and neck. Most lymphangiomas are asymptomatic, but progressive enlargement may cause feeding difficulty, airway, and cosmetic problems. According to the diameter of the majority of the cysts, lymphangiomas are divided into macrocystic (>1 cm), microcystic (<1cm), or mixed types. Sclerotherapy has been recommended as a primary treatment because surgery may result in severe tissue defect or functional complication. OK-432 is the most widely used sclerosant. Typical complications include fever, local inflammation, pain and swelling, which can usually be controlled conservatively. Bleomycin has potential risk of lung fibrosis, although there has been no such report in the literature. Acetic acid is a more potent sclerosant, which may be used as a secondary drug due to the risk of adjacent nerve damage in high concentration.The lesions are punctured with a 21 G needle under ultrasound guidance. In macrocystic lesions, we inserted 6-7 F catheters for drainage and instillation of sclerosant. While OK-432 and bleomycin are not removed, alcohol and acetic acid should be removed after indwelling for 20 minutes. Overall, an excellent response (over 90% resolution) rate of 48% was achieved. Response rate was higher in macrocystic type than microcystic type. There may be a risk of airway obstruction due to swelling and inflammation in cervical lesions. Preventive tracheostomy or intubation may be necessary in those lesions. In conclusion, sclerotherapy is a safe and effective for treatment of lymphangioma. It is recommended as a first line therapy.

Keyword

Lymphangioma; Lymphatic malformation; Sclerotherapy

MeSH Terms

Acetic Acid
Airway Obstruction
Bleomycin
Catheters
Drainage
Fever
Fibrosis
Head
Inflammation
Intubation
Lung
Lymphangioma
Lymphangioma, Cystic*
Neck
Needles
Picibanil
Sclerotherapy*
Tracheostomy
Ultrasonography
Acetic Acid
Bleomycin
Picibanil

Figure

• 

  Figure 1 Sclerotherapy in patient with macrocystic lymphangioma. (A) Pre-treatment computed tomography (CT) shows the cystic lymphangioma (arrow) in left supracervical area. (B) A 6F drainage catheter is inserted percutaneously into the lesion. A cystography shows a lobulated cystic lymphangioma. OK-432 (0.8 K, 8 mL) was injected into the cavity. (C) After 3 months, post-treatment CT shows complete resolution.

Reference

1. Kang KS, Jung PM. Clinical manifestation and treatment of lymphangioma in children: a review of 117 cases. J Korean Assoc Pediatr Surg. 2002; 8:95–100.

2. Churchill P, Otal D, Pemberton J, Ali A, Flageole H, Walton JM. Sclerotherapy for lymphatic malformations in children: a scoping review. J Pediatr Surg. 2011; 46:912–922.

3. Fronkalsrud EW. Disorders of the lymphatic system. In : Welch KJ, Randolph JG, Ravitch MM, editors. Pediatric surgery. 4th ed. Chicago: Year Book Medical;1986. p. 1506–1507.

4. Kim IK, Moon SB, Baek SH, Seo JM, Lee SK. Evaluation of intralesional injection therapy for pediatric lymphangiomas classified with MRI. J Korean Assoc Pediatr Surg. 2009; 15:113–120.

5. Won JH, Kim BM, Kim CH, Park SW, Kim MD. Percutaneous sclerotherapy of lymphangiomas with acetic acid. J Vasc Interv Radiol. 2004; 15:595–600.

6. Luzzatto C, Midrio P, Tchaprassian Z, Guglielmi M. Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Child. 2000; 82:316–318.

7. Ogita S, Tsuto T, Tokiwa K, Takahashi T. Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg. 1987; 74:690–691.

8. Zhou Q, Zheng JW, Mai HM, Luo QF, Fan XD, Su LX, Wang YA, Qin ZP. Treatment guidelines of lymphatic malformations of the head and neck. Oral Oncol. 2011; 47:1105–1109.

9. Kim MG. The effectiveness of the sclerotherapy of benign neck cyst with the use of OK-432 and 99% alcohol. Korean J Otolaryngol-Head Neck Surg. 2005; 48:1154–1160.

10. Rozman Z, Thambidorai RR, Zaleha AM, Zakaria Z, Zulfiqar MA. Lymphangioma: is intralesional bleomycin sclerotherapy effective? Biomed Imaging Interv J. 2011; 7:e18.

11. Tanigawa N, Shimomatsuya T, Takahashi K, Inomata Y, Tanaka K, Satomura K, Hikasa Y, Hashida M, Muranishi S, Sezaki H. Treatment of cystic hygroma and lymphangioma with the use of bleomycin fat emulsion. Cancer. 1987; 60:741–749.

12. Mahajan JK, Bharathi V, Chowdhary SK, Samujh R, Menon P, Rao KLN. Bleomycin as intralesional sclerosant for cystic hygromas. J Indian Assoc Pediatr Surg. 2004; 9:3–7.

13. Cahill AM, Nijs E, Ballah D, Rabinowitz D, Thompson L, Rintoul N, Hedrick H, Jacobs I, Low D. Percutaneous sclerotherapy in neonatal and infant head and neck lymphatic malformations: a single center experience. J Pediatr Surg. 2011; 46:2083–2095.

14. Impellizzeri P, Romeo C, Borruto FA, Granata F, Scalfari G, De Ponte FS, Longo M. Sclerotherapy for cervical cystic lymphatic malformations in children. Our experience with computed tomography-guided 98% sterile ethanol insertion and a review of the literature. J Pediatr Surg. 2010; 45:2473–2478.